KR102705177B1 - 종양용해성 hsv1 벡터 및 사용 방법 - Google Patents

종양용해성 hsv1 벡터 및 사용 방법 Download PDF

Info

Publication number
KR102705177B1
KR102705177B1 KR1020177034916A KR20177034916A KR102705177B1 KR 102705177 B1 KR102705177 B1 KR 102705177B1 KR 1020177034916 A KR1020177034916 A KR 1020177034916A KR 20177034916 A KR20177034916 A KR 20177034916A KR 102705177 B1 KR102705177 B1 KR 102705177B1
Authority
KR
South Korea
Prior art keywords
tumor
hsv
cells
viral vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177034916A
Other languages
English (en)
Korean (ko)
Other versions
KR20180037140A (ko
Inventor
히로시 나카시마
엔니오 안토니오 치오카
Original Assignee
더 브리검 앤드 우먼즈 하스피털, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 브리검 앤드 우먼즈 하스피털, 인크. filed Critical 더 브리검 앤드 우먼즈 하스피털, 인크.
Publication of KR20180037140A publication Critical patent/KR20180037140A/ko
Application granted granted Critical
Publication of KR102705177B1 publication Critical patent/KR102705177B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177034916A 2015-05-04 2016-05-04 종양용해성 hsv1 벡터 및 사용 방법 Active KR102705177B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156447P 2015-05-04 2015-05-04
US62/156,447 2015-05-04
PCT/US2016/030681 WO2016179226A1 (en) 2015-05-04 2016-05-04 Oncolytic hsv1 vector and methods of use

Publications (2)

Publication Number Publication Date
KR20180037140A KR20180037140A (ko) 2018-04-11
KR102705177B1 true KR102705177B1 (ko) 2024-09-11

Family

ID=57218316

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177034916A Active KR102705177B1 (ko) 2015-05-04 2016-05-04 종양용해성 hsv1 벡터 및 사용 방법

Country Status (10)

Country Link
US (1) US10806761B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981438A1 (cg-RX-API-DMAC7.html)
JP (1) JP6865736B2 (cg-RX-API-DMAC7.html)
KR (1) KR102705177B1 (cg-RX-API-DMAC7.html)
CN (1) CN108025088B (cg-RX-API-DMAC7.html)
AU (2) AU2016257910B2 (cg-RX-API-DMAC7.html)
CA (1) CA2988196C (cg-RX-API-DMAC7.html)
DK (1) DK3291841T3 (cg-RX-API-DMAC7.html)
ES (1) ES2903349T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016179226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582574A (zh) * 2017-03-13 2019-12-17 麻省理工学院 合成启动子
KR101974169B1 (ko) 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
SG11202105422RA (en) * 2018-11-29 2021-06-29 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
CA3132867A1 (en) * 2019-03-14 2020-09-17 Research Institute At Nationwide Children's Hospital Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
KR102333650B1 (ko) * 2019-11-08 2021-12-01 한국해양과학기술원 신규한 인간 상피세포성장인자 융합 단백질 및 이의 용도
US20240024392A1 (en) * 2020-12-04 2024-01-25 Immvira Co., Limited Oncolytic herpes simplex type 1 viruses for treatment of brain tumors
WO2026076297A1 (en) * 2024-10-03 2026-04-09 Candel Therapeutics, Inc. Compositions and methods for treating melanoma using an oncolytic virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272686A1 (en) 2007-10-17 2010-10-28 The Ohio State University Research Founddation Oncolytic virus
WO2014078529A1 (en) * 2012-11-14 2014-05-22 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vectors and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
WO2002053576A1 (en) 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts
WO2005080581A2 (en) * 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
WO2005103237A1 (ja) * 2004-03-31 2005-11-03 Tomoki Todo 組換え単純ヘルペスウイルスの作製方法
EP2123051B1 (en) * 2006-12-18 2010-11-10 Koninklijke Philips Electronics N.V. Image compression and decompression
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272686A1 (en) 2007-10-17 2010-10-28 The Ohio State University Research Founddation Oncolytic virus
WO2014078529A1 (en) * 2012-11-14 2014-05-22 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vectors and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Res., Vol.65, No.24, pp.1193-1198(2005.12.15.)*

Also Published As

Publication number Publication date
AU2016257910B2 (en) 2021-06-24
CA2988196C (en) 2021-04-27
CA2988196A1 (en) 2016-11-10
EP3291841B1 (en) 2021-10-20
US20180133269A1 (en) 2018-05-17
AU2021232778B2 (en) 2024-12-19
CN108025088B (zh) 2021-08-10
AU2016257910A1 (en) 2017-12-21
AU2021232778A1 (en) 2021-10-14
EP3291841A1 (en) 2018-03-14
ES2903349T3 (es) 2022-04-01
KR20180037140A (ko) 2018-04-11
WO2016179226A1 (en) 2016-11-10
DK3291841T3 (da) 2022-01-10
JP2018518986A (ja) 2018-07-19
CN108025088A (zh) 2018-05-11
EP3981438A1 (en) 2022-04-13
US10806761B2 (en) 2020-10-20
EP3291841A4 (en) 2018-12-05
JP6865736B2 (ja) 2021-04-28

Similar Documents

Publication Publication Date Title
AU2021232778B2 (en) Oncolytic HSV1 vector and methods of use
AU2019204982B2 (en) Recombinant HCMV and RhCMV Vectors and Uses Thereof
AU2018240515B2 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
DK2753355T3 (en) ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
KR20230111189A (ko) 재프로그램 가능한 iscb 뉴클레아제 및 이의 용도
KR101668163B1 (ko) Cmv용 백신으로서의 조건부 복제 시토메갈로바이러스
CN110101723B (zh) 一种用于治疗肿瘤的伪狂犬病毒
AU2015289560B2 (en) Human cytomegalovirus comprising exogenous antigens
AU2018201717A1 (en) Optimal maize loci
CN107574154A (zh) 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
WO1998020016A1 (en) Novel coding sequences from herpes simplex virus type-2
KR20240035382A (ko) 아데노바이러스 유전자 요법 벡터
KR20200083540A (ko) 시토메갈로바이러스의 안정한 제형
KR20210053923A (ko) 항종양 면역 반응을 자극하는 키메라 종양 용해성 허피스바이러스
CN113559134B (zh) 一种用于肿瘤治疗的药物
CN101671656B (zh) 溶瘤ⅰ型单纯疱疹病毒靶向和杀伤前列腺肿瘤细胞的方法
CA3255805A1 (en) COMPOSITIONS AND METHODS INTENDED FOR VIRAL VECTORS
KR102039631B1 (ko) U38, u40 및 u41의 일부 서열을 포함하는 재조합 단순 헤르페스 바이러스 셔틀 벡터의 제조 방법
KR102933002B1 (ko) 강력한 암 치료제로서의 융합체 종양용해성 단순 헤르페스 돌연변이체
CN114761030A (zh) 具有诱导的抗肿瘤免疫的溶瘤病毒疗法
NL2023464B1 (en) Oncolytic Non-human adenoviruses and uses thereof
KR102032446B1 (ko) 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
KR20210090086A (ko) ATAC-seq 데이터 정규화 및 이의 활용 방법
KR102039634B1 (ko) U38, u340 및 u41의 일부 서열을 포함하는 재조합 단순 헤르페스 바이러스 셔틀 벡터
KR102052718B1 (ko) Icp6 영역에 암 치료 유전자를 포함하는 셔틀벡터와 형질 전환 단계를 포함하는 hsv-1 벡터의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601